{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:25Z","timestamp":1792788325843,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82170184"],"award-info":[{"award-number":["82170184"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-026-01801-y","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:15:59Z","timestamp":1783509359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating ANP32A expression with Ann Arbor stage refines prognostic stratification in extranodal NK\/T-cell lymphoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Yajun","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wugan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"2","key":"1801_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/hon.2944","volume":"41","author":"X He","year":"2023","unstructured":"He X, Gao Y, Li Z, et al. Review on natural killer\/T-cell lymphoma. Hematol Oncol. 2023;41(2):221\u20139.","journal-title":"Hematol Oncol"},{"issue":"4","key":"1801_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.seminhematol.2022.10.002","volume":"59","author":"E Tse","year":"2022","unstructured":"Tse E, Fox CP, Glover A, et al. Extranodal natural killer\/T-cell lymphoma: An overview on pathology and clinical management. Semin Hematol. 2022;59(4):198\u2013209.","journal-title":"Semin Hematol"},{"key":"1801_CR3","first-page":"101550","volume":"62","author":"WL Chan","year":"2025","unstructured":"Chan WL, Hue SS, Deng L, et al. Extranodal NK\/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications. Lancet Reg Health West Pac. 2025;62:101550.","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"1801_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-023-01483-9","volume":"16","author":"XP Tian","year":"2023","unstructured":"Tian XP, Cao Y, Cai J, et al. Novel target and treatment agents for natural killer\/T-cell lymphoma . J Hematol Oncol. 2023;16(1):78.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1801_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong J, Cui BW, Wang N, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma . Cancer Cell. 2020;37(3):403\u2013e419406.","journal-title":"Cancer Cell"},{"key":"1801_CR6","doi-asserted-by":"publisher","first-page":"1088685","DOI":"10.3389\/fimmu.2023.1088685","volume":"14","author":"Z Yan","year":"2023","unstructured":"Yan Z, Yao S, Wang Z, et al. Treatment of extranodal NK\/T-cell lymphoma: From past to future . Front Immunol. 2023;14:1088685.","journal-title":"Front Immunol"},{"issue":"4","key":"1801_CR7","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3026(19)30283-2","volume":"7","author":"CP Fox","year":"2020","unstructured":"Fox CP, Civallero M, Ko YH, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020;7(4):e284\u201394.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1801_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4143\/crt.2022.015","volume":"55","author":"S Kang","year":"2023","unstructured":"Kang S, Cho H, Kim S, et al. A New Prognostic Index for Extranodal Natural Killer\/T-Cell Lymphoma:Incorporation of Serum \u03b2-2 Microglobulin to PINK. Cancer Res Treat. 2023;55(1):314\u201324.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"1801_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389\u2013400.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1801_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/life12010073","volume":"12","author":"H Kim","year":"2022","unstructured":"Kim H, Ko YH. The Pathologic and Genetic Characteristics of Extranodal NK\/T-Cell Lymphoma. Life (Basel), 2022,12(1).","journal-title":"Life"},{"issue":"1","key":"1801_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13000-023-01413-w","volume":"18","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Liu E, Zhang D, et al. The expression and clinical significance of PLK1\/p-PLK1 protein in NK\/T cell Lymphoma. Diagn Pathol. 2023;18(1):129.","journal-title":"Diagn Pathol"},{"issue":"8","key":"1801_CR12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/life11080838","volume":"11","author":"JY Chan","year":"2021","unstructured":"Chan JY, Lim JQ, Ong CK. Towards Next Generation Biomarkers in Natural Killer\/T-Cell Lymphoma. Life (Basel), 2021,11(8).","journal-title":"Life"},{"issue":"2","key":"1801_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/diagnostics12020409","volume":"12","author":"KM Sun","year":"2022","unstructured":"Sun KM, Wong YH, Cheung KC et al. Update on Molecular Diagnosis in Extranodal NK\/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine . Diagnostics (Basel), 2022,12(2).","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"1801_CR14","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/s41375-018-0010-7","volume":"32","author":"X Yang","year":"2018","unstructured":"Yang X, Lu B, Sun X, et al. ANP32A regulates histone H3 acetylation and promotes leukemogenesis . Leukemia. 2018;32(7):1587\u201397.","journal-title":"Leukemia"},{"issue":"12","key":"1801_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41408-017-0031-x","volume":"7","author":"X Sun","year":"2017","unstructured":"Sun X, Lu B, Han C, et al. ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia . Blood Cancer J. 2017;7(12):661.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1801_CR16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/cac2.12356","volume":"42","author":"R Wei","year":"2022","unstructured":"Wei R, Zhu Y, Zhang Y, et al. AIMP1 promotes multiple myeloma malignancy through interacting with ANP32A to mediate histone H3 acetylation . Cancer Commun (Lond). 2022;42(11):1185\u2013206.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1801_CR17","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1097\/HS9.0000000000000822","volume":"7","author":"D Huang","year":"2023","unstructured":"Huang D, Li Q, Li X, et al. The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK\/T-cell Lymphoma . Hemasphere. 2023;7(1):e822.","journal-title":"Hemasphere"},{"issue":"8","key":"1801_CR18","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/annonc\/mdm183","volume":"18","author":"SJ Kim","year":"2007","unstructured":"Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I\/II extranodal NK\/T-cell lymphoma, nasal type . Ann Oncol. 2007;18(8):1382\u20137.","journal-title":"Ann Oncol"},{"issue":"10","key":"1801_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12032-014-0218-y","volume":"31","author":"L Jiang","year":"2014","unstructured":"Jiang L, Li P, Wang H, et al. Prognostic significance of Ki-67 antigen expression in extranodal natural killer\/T-cell lymphoma, nasal type . Med Oncol. 2014;31(10):218.","journal-title":"Med Oncol"},{"key":"1801_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.humpath.2018.08.025","volume":"83","author":"J Liu","year":"2019","unstructured":"Liu J, Liang L, Huang S, et al. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK\/T-cell lymphoma, nasal type, is associated with disease progression and prognosis . Hum Pathol. 2019;83:166\u201376.","journal-title":"Hum Pathol"},{"issue":"1","key":"1801_CR21","doi-asserted-by":"publisher","first-page":"10342","DOI":"10.1038\/s41598-021-89754-8","volume":"11","author":"JY Lee","year":"2021","unstructured":"Lee JY, Kim JH, Bang H, et al. EGR1 as a potential marker of prognosis in extranodal NK\/T-cell lymphoma . Sci Rep. 2021;11(1):10342.","journal-title":"Sci Rep"},{"key":"1801_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40364-020-00205-4","volume":"8","author":"Q Li","year":"2020","unstructured":"Li Q, Zhang W, Li J, et al. Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK\/T-cell lymphoma . Biomark Res. 2020;8:27.","journal-title":"Biomark Res"},{"issue":"5","key":"1801_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","volume":"469","author":"WY Kim","year":"2016","unstructured":"Kim WY, Jung HY, Nam SJ, et al. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis . Virchows Arch. 2016;469(5):581\u201390.","journal-title":"Virchows Arch"},{"issue":"1","key":"1801_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41598-021-02515-5","volume":"12","author":"Y Feng","year":"2022","unstructured":"Feng Y, Feng X, Jing C, et al. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK\/T cell lymphoma . Sci Rep. 2022;12(1):36.","journal-title":"Sci Rep"},{"issue":"9","key":"1801_CR25","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3324\/haematol.2023.283811","volume":"109","author":"C Bi","year":"2024","unstructured":"Bi C, Huang Y, Ali R, et al. MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications . Haematologica. 2024;109(9):2810\u201321.","journal-title":"Haematologica"},{"issue":"2","key":"1801_CR26","doi-asserted-by":"publisher","first-page":"100859","DOI":"10.1016\/j.xcrm.2022.100859","volume":"4","author":"XP Tian","year":"2023","unstructured":"Tian XP, Zhang YC, Lin NJ, et al. Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer\/T cell lymphoma . Cell Rep Med. 2023;4(2):100859.","journal-title":"Cell Rep Med"},{"key":"1801_CR27","doi-asserted-by":"publisher","first-page":"1109715","DOI":"10.3389\/fonc.2023.1109715","volume":"13","author":"JJ Kim","year":"2023","unstructured":"Kim JJ, Kim HY, Choi Z, et al. In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer\/T-cell lymphomas . Front Oncol. 2023;13:1109715.","journal-title":"Front Oncol"},{"issue":"6","key":"1801_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.21037\/atm.2020.02.54","volume":"8","author":"S Huang","year":"2020","unstructured":"Huang S, Huang Z, Ma C, et al. Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia . Ann Transl Med. 2020;8(6):345.","journal-title":"Ann Transl Med"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-026-01801-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:42:29Z","timestamp":1790844149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-026-01801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1801"],"URL":"https:\/\/doi.org\/10.1186\/s13000-026-01801-y","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"21 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (Approval No. 2025-KY-1374). The requirement for informed consent was waived by the Ethics Committee because of the retrospective nature of the study and the use of archived tissue specimens and anonymized clinical data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"70"}}